Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jan;34(1):8–12. doi: 10.1128/aac.34.1.8

Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

T D Gootz 1, J F Barrett 1, J A Sutcliffe 1
PMCID: PMC171510  PMID: 2158274

Full text

PDF
8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amacher D. E., Paillet S., Ray V. A. Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells. I. Application to genetic toxicological testing. Mutat Res. 1979 Dec;64(6):391–406. doi: 10.1016/0165-1161(79)90109-2. [DOI] [PubMed] [Google Scholar]
  2. Barrett J. F., Sutcliffe J. A., Gootz T. D. In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother. 1990 Jan;34(1):1–7. doi: 10.1128/aac.34.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bredberg A., Brant M., Riesbeck K., Azou Y., Forsgren A. 4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction. Mutat Res. 1989 Mar;211(1):171–180. doi: 10.1016/0027-5107(89)90117-6. [DOI] [PubMed] [Google Scholar]
  4. Castora F. J., Simpson M. V. Search for a DNA gyrase in mammalian mitochondria. J Biol Chem. 1979 Nov 25;254(22):11193–11195. [PubMed] [Google Scholar]
  5. Castora F. J., Vissering F. F., Simpson M. V. The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. Biochim Biophys Acta. 1983 Sep 9;740(4):417–427. doi: 10.1016/0167-4781(83)90090-8. [DOI] [PubMed] [Google Scholar]
  6. Christ W., Lehnert T., Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S141–S146. doi: 10.1093/clinids/10.supplement_1.s141. [DOI] [PubMed] [Google Scholar]
  7. Chu D. T., Fernandes P. B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989 Feb;33(2):131–135. doi: 10.1128/aac.33.2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clive D., Spector J. F. Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells. Mutat Res. 1975 Feb;31(1):17–29. doi: 10.1016/0165-1161(75)90059-x. [DOI] [PubMed] [Google Scholar]
  9. DeMarini D. M., Brock K. H., Doerr C. L., Moore M. M. Mutagenicity and clastogenicity of teniposide (VM-26) in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. Mutat Res. 1987 Mar;187(3):141–149. doi: 10.1016/0165-1218(87)90081-4. [DOI] [PubMed] [Google Scholar]
  10. Detera S. D., Becerra S. P., Swack J. A., Wilson S. H. Studies on the mechanism of DNA polymerase alpha. Nascent chain elongation, steady state kinetics, and the initiation phase of DNA synthesis. J Biol Chem. 1981 Jul 10;256(13):6933–6943. [PubMed] [Google Scholar]
  11. Dillehay L. E., Denstman S. C., Williams J. R. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Cancer Res. 1987 Jan 1;47(1):206–209. [PubMed] [Google Scholar]
  12. Domagala J. M., Hagen S. E., Heifetz C. L., Hutt M. P., Mich T. F., Sanchez J. P., Trehan A. K. 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. J Med Chem. 1988 Mar;31(3):503–506. doi: 10.1021/jm00398a003. [DOI] [PubMed] [Google Scholar]
  13. Duguet M., Lavenot C., Harper F., Mirambeau G., De Recondo A. M. DNA topoisomerases from rat liver: physiological variations. Nucleic Acids Res. 1983 Feb 25;11(4):1059–1075. doi: 10.1093/nar/11.4.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fairfield F. R., Bauer W. R., Simpson M. V. Mitochondria contain a distinct DNA topoisomerase. J Biol Chem. 1979 Oct 10;254(19):9352–9354. [PubMed] [Google Scholar]
  15. Featherstone T., Marshall P. D., Evans H. J. Problems and pitfalls in assessing human T-lymphocyte mutant frequencies. Mutat Res. 1987 Aug;179(2):215–230. doi: 10.1016/0027-5107(87)90312-5. [DOI] [PubMed] [Google Scholar]
  16. Forsgren A., Bredberg A., Pardee A. B., Schlossman S. F., Tedder T. F. Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother. 1987 May;31(5):774–779. doi: 10.1128/aac.31.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Forsgren A., Schlossman S. F., Tedder T. F. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother. 1987 May;31(5):768–773. doi: 10.1128/aac.31.5.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Green M. H. Short-term tests and the myth of the non-clastogenic mutagen. Mutagenesis. 1988 Sep;3(5):369–371. doi: 10.1093/mutage/3.5.369. [DOI] [PubMed] [Google Scholar]
  19. Harris C. C. Human tissues and cells in carcinogenesis research. Cancer Res. 1987 Jan 1;47(1):1–10. [PubMed] [Google Scholar]
  20. Holden H. E., Barett J. F., Huntington C. M., Muehlbauer P. A., Wahrenburg M. G. Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction. Environ Mol Mutagen. 1989;13(3):238–252. doi: 10.1002/em.2850130308. [DOI] [PubMed] [Google Scholar]
  21. Hsieh T., Brutlag D. ATP-dependent DNA topoisonmerase from D. melanogaster reversibly catenates duplex DNA rings. Cell. 1980 Aug;21(1):115–125. doi: 10.1016/0092-8674(80)90119-1. [DOI] [PubMed] [Google Scholar]
  22. Hussy P., Maass G., Tümmler B., Grosse F., Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073–1078. doi: 10.1128/aac.29.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jack D. B. Recent advances in pharmaceutical chemistry. The 4-quinolone antibiotics. J Clin Hosp Pharm. 1986 Apr;11(2):75–93. doi: 10.1111/j.1365-2710.1986.tb00831.x. [DOI] [PubMed] [Google Scholar]
  24. Klopman G., Macina O. T., Levinson M. E., Rosenkranz H. S. Computer automated structure evaluation of quinolone antibacterial agents. Antimicrob Agents Chemother. 1987 Nov;31(11):1831–1840. doi: 10.1128/aac.31.11.1831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lave L. B., Omenn G. S. Cost-effectiveness of short-term tests for carcinogenicity. Nature. 1986 Nov 6;324(6092):29–34. doi: 10.1038/324029a0. [DOI] [PubMed] [Google Scholar]
  26. Li A. P., Carver J. H., Choy W. N., Hsie A. W., Gupta R. S., Loveday K. S., O'Neill J. P., Riddle J. C., Stankowski L. F., Jr, Yang L. L. A guide for the performance of the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. Mutat Res. 1987 Oct;189(2):135–141. doi: 10.1016/0165-1218(87)90019-x. [DOI] [PubMed] [Google Scholar]
  27. Lutz W. K., Maier P. Genotoxic and epigenetic chemical carcinogenesis: one process, different mechanisms. Trends Pharmacol Sci. 1988 Sep;9(9):322–326. doi: 10.1016/0165-6147(88)90103-4. [DOI] [PubMed] [Google Scholar]
  28. Maron D. M., Ames B. N. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983 May;113(3-4):173–215. doi: 10.1016/0165-1161(83)90010-9. [DOI] [PubMed] [Google Scholar]
  29. Maura A., Pino A. Evaluation of the DNA-damaging and mutagenic activity of oxolinic and pipemidic acids by the granuloma pouch assay. Mutagenesis. 1988 Sep;3(5):397–401. doi: 10.1093/mutage/3.5.397. [DOI] [PubMed] [Google Scholar]
  30. Miller K. G., Liu L. F., Englund P. T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem. 1981 Sep 10;256(17):9334–9339. [PubMed] [Google Scholar]
  31. Mirsalis J. C., Butterworth B. E. Detection of unscheduled DNA synthesis in hepatocytes isolated from rats treated with genotoxic agents: an in vivo- in vitro assay for potential carcinogens and mutagens. Carcinogenesis. 1980 Jul;1(7):621–625. doi: 10.1093/carcin/1.7.621. [DOI] [PubMed] [Google Scholar]
  32. Mitelman F., Kolnig A. M., Strömbeck B., Norrby R., Kromann-Andersen B., Sommer P., Wadstein J. No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother. 1988 Jun;32(6):936–937. doi: 10.1128/aac.32.6.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Oomori Y., Yasue T., Aoyama H., Hirai K., Suzue S., Yokota T. Effects of fleroxacin on HeLa cell functions and topoisomerase II. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):91–97. doi: 10.1093/jac/22.supplement_d.91. [DOI] [PubMed] [Google Scholar]
  34. Osheroff N., Shelton E. R., Brutlag D. L. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem. 1983 Aug 10;258(15):9536–9543. [PubMed] [Google Scholar]
  35. Rusquet R., Bonhommet M., David J. C. Quinolone antibiotics inhibit eucaryotic DNA polymerase alpha and beta, terminal deoxynucleotidyl transferase but not DNA ligase. Biochem Biophys Res Commun. 1984 Jun 29;121(3):762–769. doi: 10.1016/0006-291x(84)90744-7. [DOI] [PubMed] [Google Scholar]
  36. Sutcliffe J. A., Gootz T. D., Barrett J. F. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob Agents Chemother. 1989 Dec;33(12):2027–2033. doi: 10.1128/aac.33.12.2027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tabary X., Moreau N., Dureuil C., Le Goffic F. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I. Antimicrob Agents Chemother. 1987 Dec;31(12):1925–1928. doi: 10.1128/aac.31.12.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tennant R. W., Margolin B. H., Shelby M. D., Zeiger E., Haseman J. K., Spalding J., Caspary W., Resnick M., Stasiewicz S., Anderson B. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science. 1987 May 22;236(4804):933–941. doi: 10.1126/science.3554512. [DOI] [PubMed] [Google Scholar]
  39. Uemura T., Morikawa K., Yanagida M. The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases. EMBO J. 1986 Sep;5(9):2355–2361. doi: 10.1002/j.1460-2075.1986.tb04504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Vanderkerken K., Vanparys P., Verschaeve L., Kirsch-Volders M. The mouse bone marrow micronucleus assay can be used to distinguish aneugens from clastogens. Mutagenesis. 1989 Jan;4(1):6–11. doi: 10.1093/mutage/4.1.6. [DOI] [PubMed] [Google Scholar]
  41. Wright H. T., Nurse K. C., Goldstein D. J. Nalidixic acid, oxolinic acid, and novobiocin inhibit yeast glycyl- and leucyl-transfer RNA synthetases. Science. 1981 Jul 24;213(4506):455–456. doi: 10.1126/science.7017932. [DOI] [PubMed] [Google Scholar]
  42. Young S. S. Do short-term tests predict rodent carcinogenicity? Science. 1988 Sep 2;241(4870):1232–1233. doi: 10.1126/science.3413488. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES